MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-02-2026
Supernus Pharmaceuticals Operating Cycle 2011-2026 | SUPN
Annual Operating Cycle Supernus Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 492 | 387 | 461 | 457 | 418 | 341 | 665 | 702 | 470 | 582 | 611 | 904 | 2.53 K | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.53 K | 341 | 694 |
Quarterly Operating Cycle Supernus Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 438 | 332 | 388 | - | 420 | 446 | 519 | - | 488 | 487 | 447 | - | 379 | 469 | 533 | - | 382 | 283 | 394 | - | 289 | 627 | 933 | 79.3 | 582 | 677 | 749 | 81 | 648 | 730 | 669 | 67.7 | 424 | 464 | 597 | 60.8 | 66.7 | 73.4 | 69.6 | 54.1 | 60.1 | 66.3 | 68.5 | 50.5 | 70.2 | 57.1 | 113 | 44.6 | 367 | 1.64 K | 1.57 K | 21.4 | 251 | - | 28.1 | 139 | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.64 K | 21.4 | 378 |
Operating Cycle of other stocks in the Biotechnology industry
| Issuer | Operating Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
I-Mab
IMAB
|
271 | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B |  USA |
 |
Midatech Pharma plc
MTP
|
245 | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
32 | - | -1.52 % | $ 24.7 M | USA |
 |
Acorda Therapeutics
ACOR
|
394 | - | -24.86 % | $ 820 K | USA |
 |
Advaxis
ADXS
|
88.1 | - | -9.65 % | $ 45.9 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - |  Russia |
 |
Aeterna Zentaris
AEZS
|
115 | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K | USA |
 |
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
102 | $ 330.34 | 3.6 % | $ 43.3 B | USA |
 |
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | USA |
 |
Evogene Ltd.
EVGN
|
30 | $ 0.79 | 1.22 % | $ 27.9 M |  Israel |
 |
Завод ДИОД
DIOD
|
64.6 | - | - | - | Russia |
 |
Фармсинтез
LIFE
|
9.78 | - | - | - | Russia |
 |
Aptorum Group Limited
APM
|
4.89 | $ 0.89 | -4.33 % | $ 4.85 M | China |
 |
Aptinyx
APTX
|
46.9 | - | -39.0 % | $ 4.57 M | USA |
 |
Teligent, Inc.
TLGT
|
167 | - | -13.85 % | $ 16.1 M | USA |
 |
AbbVie
ABBV
|
350 | $ 206.69 | -1.01 % | $ 366 B | USA |
 |
Aquestive Therapeutics
AQST
|
223 | $ 4.09 | -0.97 % | $ 437 M | USA |
 |
Viela Bio, Inc.
VIE
|
174 | - | - | $ 2.91 B | USA |
 |
AbCellera Biologics
ABCL
|
173 | $ 3.39 | -3.69 % | $ 1.01 B | Canada |
 |
Arcturus Therapeutics Holdings
ARCT
|
21.2 | $ 8.22 | 2.37 % | $ 225 M | Israel |
 |
Ardelyx
ARDX
|
1.05 K | $ 5.97 | 0.51 % | $ 1.44 B | USA |
 |
Grifols, S.A.
GRFS
|
0.000171 | $ 8.23 | -0.12 % | $ 6.83 B |  Spain |
 |
Akebia Therapeutics
AKBA
|
210 | $ 1.32 | -4.35 % | $ 339 M | USA |